Outset Medical (NYSE: OM) director granted 10,667 RSUs in new equity award

Rhea-AI Filing Summary

OBOYLE KEVIN C reported acquisition or exercise transactions in this Form 4 filing.

Outset Medical, Inc. director Kevin C. O’Boyle received an equity award in the form of restricted stock units covering 10,667 shares of common stock. The award was recorded at a price of $0.00 per share as a compensation grant, not a market purchase.

Following this award, O’Boyle directly holds 34,785 shares of Outset Medical common stock. According to the disclosure, 100% of the shares underlying these RSUs will vest upon the earlier of the one-year anniversary of the grant date or the company’s next Annual Meeting of Stockholders.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider OBOYLE KEVIN C

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10,667	$0.00	--

Holdings After Transaction: Common Stock — 34,785 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 10,667 shares Grant price: $0.00 per share Shares after transaction: 34,785 shares +1 more

4 metrics

RSU grant size 10,667 shares Restricted stock unit award to director on 2026-06-04

Grant price $0.00 per share Reported transaction price for RSU-related common stock

Shares after transaction 34,785 shares Director’s total direct holdings following the RSU award

Vesting condition 100% cliff vesting Earlier of one-year after grant or next Annual Meeting of Stockholders

Key Terms

restricted stock units, Annual Meeting of Stockholders, Grant, award, or other acquisition

3 terms

restricted stock units financial

"100% of the shares underlying these RSUs will vest upon the earlier"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Annual Meeting of Stockholders financial

"the date of the Issuer's next Annual Meeting of Stockholders"

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OBOYLE KEVIN C

(Last) (First) (Middle)

3052 ORCHARD DRIVE

(Street)

SAN JOSE CALIFORNIA 95134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Outset Medical, Inc. [ OM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		A		10,667(1)	A	$0.0	34,785	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. 100% of the shares underlying these RSUs will vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the Issuer's next Annual Meeting of Stockholders

	By: John L Brottem For: Kevin O'Boyle	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Outset Medical (OM) director Kevin O’Boyle report in this Form 4?

Kevin O’Boyle reported receiving a grant of 10,667 restricted stock units of Outset Medical common stock. This is a compensation award, not an open-market trade, and increases his directly held position to 34,785 shares after the transaction.

Is the Kevin O’Boyle Form 4 for Outset Medical (OM) a stock purchase or a grant?

The Form 4 shows a grant, not a purchase. O’Boyle acquired 10,667 shares through a restricted stock unit award coded as an “A” transaction, meaning a grant or other acquisition, with a reported price of $0.00 per share as compensation.

How many Outset Medical (OM) shares does Kevin O’Boyle hold after this RSU award?

After the reported RSU award, Kevin O’Boyle directly holds 34,785 shares of Outset Medical common stock. This total includes the 10,667 shares associated with the new restricted stock unit grant disclosed in the Form 4 filing.

When do Kevin O’Boyle’s new Outset Medical (OM) RSUs vest?

All 10,667 RSUs will vest 100% upon the earlier of two dates: the one-year anniversary of the grant date or the date of Outset Medical’s next Annual Meeting of Stockholders, according to the vesting condition disclosed in the footnote.

Does the Outset Medical (OM) Form 4 indicate any stock sales by Kevin O’Boyle?

No stock sales are reported in this Form 4. The filing only shows an acquisition via a restricted stock unit grant of 10,667 shares, with no sell transactions or dispositions listed in the transaction summary or detail.